# CareDx, Inc.: Form 10-Q for the period ended Mar 31, 2018

- Company: [CareDx, Inc.](/companies/cdna.md) (CIK 1217234)
- Form: 10-Q
- Filed: 2018-05-10
- Accepted by EDGAR: May 10, 2018, 17:10 ET
- Period: 2018-03-31
- Accession: 0001564590-18-013045
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1217234/000156459018013045/cdna-10q_20180331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1217234/000156459018013045/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2018-01-01 to 2018-03-31 | $2.3m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months, 2018-01-01 to 2018-03-31 | $3.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2018-01-01 to 2018-03-31 | −$5.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2018-01-01 to 2018-03-31 | −$424.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-01-01 to 2018-03-31 | −$9.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-01-01 to 2018-03-31 | −$0.30 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-01-01 to 2018-03-31 | −$0.30 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-01-01 to 2018-03-31 | 29,615,441 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 3 months, 2018-01-01 to 2018-03-31 | $62.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2018-03-31 | $18.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-03-31 | $32.7m | us-gaap:AssetsCurrent |
| Total assets | at 2018-03-31 | $79.0m | us-gaap:Assets |
| Current liabilities | at 2018-03-31 | $13.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-03-31 | $45.6m | us-gaap:Liabilities |
| Long-term debt | at 2018-03-31 | $9.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2018-03-31 | $461.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2018-03-31 | $33.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 51,050 characters.

*The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included elsewhere in Item 1 of Part I of this Quarterly Report on Form 10-Q and with the audited financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, originally filed with the Securities and Exchange Commission, or the SEC, on March 22, 2018.*

### SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” and the negative and plural forms of these words and similar expressions are intended to identify forward-looking statements.

These forward-looking statements may include, but are not limited to, statements concerning the following:

- our ability to generate revenue from sales of AlloMap, AlloSure and future post-transplant solutions, if any, and our ability to achieve commercial success of these post-transplant solutions;
- our ability to generate revenue from sales of Olerup SSP, Olerup SBT, Olerup QTYPE, and future pre-transplant solutions, if any, and our ability to increase the commercial success of these pre-transplant products;
- our ability to generate revenue from the license and commercialization agreement with Illumina, Inc.;
- our plans and ability to develop and commercialize new solutions for the surveillance of heart, kidney, and other solid organ transplant recipients;
- our plans and ability to continue updating our sequence specific primer products and technology to maintain our leading position in the SSP market;
- our plans and ability to develop, commercialize, and/or distribute new Human Leukocyte Antigen, or HLA, typing, and Next Generation Sequencing technology and pre-transplant solutions;
- our ability to obtain additional financing on terms favorable to us, or at all;
- our ability to regain eligibility to use Registration Statements on Form S-3 for capital-raising transactions;
- our ability to obtain, maintain and expand reimbursement coverage from payers for AlloMap, AlloSure and other future post-transplant solutions, if any;
- the outcome or success of our clinical trial collaborations and registry studies;
- our dependence on certain of our suppliers, service providers, and other distribution partners;
- our compliance with federal, state and foreign regulatory requirements;
- the favorable review of our pre- and post-transplant offerings, and our future solutions, if any, in peer-reviewed publications;
- our ability to protect and enforce our intellectual property rights, our strategies regarding filing additional patent applications to strengthen our intellectual property rights, and our ability to defend against intellectual property claims that may be brought against us;
- our anticipated cash needs and our anticipated uses of our funds, including our estimates regarding operating expenses and capital requirements;
- our ability to meet our obligations under our equity financing agreements and debt agreements;
- anticipated trends and challenges in our business and the markets in which we operate;
- disruptions to our business, including disruptions at our laboratories and manufacturing facilities;
- our ability to retain key members of our management team;
- our ability to make successful acquisitions or investments and to manage the integration of such acquisitions or investments;
- our ability to successfully defend against or settle any litigation brought against us or other legal matters or disputes;
- our ability to expand internationally; and
- our ability to comply with the requirements of being a public company.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the section entitled “Risk Factors” in this Quarterly Report on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially and adversely from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.

You should read this report and the documents that we reference in this report and have filed with the SEC as exhibits with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. We qualify all forward-looking statements by these cautionary statements.

### Overview and Recent Highlights

We are a global transplant diagnostics company with product offerings along the pre- and post-transplant continuum. We focus on discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients.

### AlloMap

Our first commercialized post-transplant testing solution, the AlloMap heart transplant molecular test, or AlloMap, is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate-to-severe acute cellular rejection. Since 2008, we have sought to expand the adoption and utilization of our AlloMap solution through ongoing studies to substantiate the clinical utility and actionability of AlloMap, secure positive reimbursement decisions for AlloMap from large private and public payers, develop and enhance our relationships with key members of the transplant community, including opinion leaders at major transplant centers, and explore opportunities and technologies for the development of additional solutions for post-transplant surveillance. We believe the use of AlloMap, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a heart transplant. In particular, we believe AlloMap can improve patient care by helping healthcare providers avoid the use of unnecessary, invasive surveillance biopsies and determine the appropriate dosage levels of immunosuppressants. AlloMap has received 510(k) clearance from the U.S. Food and Drug Administration, or FDA, for marketing and sale as a test to aid in the identification of recipients with a low probability of moderate or severe acute cellular rejection.

AlloMap has received positive coverage decisions for reimbursement from Medicare. The 2018 reimbursement rate for AlloMap is $3,240, which represents a 14% increase over the 2017 reimbursement rate. AlloMap has also received positive coverage decisions for reimbursement from many of the largest U.S. private payers, including Aetna, Anthem, Cigna, Health Care Services Corporation (HCSC), Humana, Kaiser Foundation Health Plan, Inc., and TRICARE.

We have also successfully completed a number of landmark clinical trials in the transplant field demonstrating the clinical utility of AlloMap for surveillance of heart transplant recipients. We initially established the analytical and clinical validity of AlloMap on the basis of our Cardiac Transplanted Organ Rejection Gene Expression Observational (Deng, M. et al., Am J Transplantation 2006), or CARGO, study, which was published in the *American Journal of Transplantation*. A subsequent clinical utility trial, Invasive Monitoring Attenuation through Gene Expression (Pham MX et al., N. Eng. J. Med., 2010), or IMAGE, published in The New England Journal of Medicine, demonstrated that clinical outcomes in recipients managed with AlloMap surveillance were equivalent

(non-inferior) to outcomes in recipients managed with biopsies. The results of our clinical trials have also been presented at major medical society congresses and published in peer-reviewed publications in leading scientific and medical journals.

During the first three months of 2018, there were 3,847 AlloMap patient test results provided to 116 of the approximately 130 heart transplant management centers in the United States.

### AlloSure

AlloSure, our recently launched commercial transplant surveillance solution, applies proprietary next generation sequencing technology to measure donor-derived cell free DNA, or dd-cfDNA in the blood stream emanating from the donor kidney or heart. We believe AlloSure may help clinicians determine rejection-specific activity manifested as cell damage in the transplanted heart, kidney and other solid organs, irrespective of the type of organ transplanted. We also believe the use of AlloSure, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a kidney transplant. In particular, we believe AlloSure can improve patient care by helping healthcare providers to reduce the use of invasive biopsies and determine the appropriate dosage levels of immunosuppressants. Effective October 9, 2017, AlloSure became available for commercial testing with Medicare coverage and reimbursement. The Medicare reimbursement rate for AlloSure is $2,841. AlloSure has also received payment from private payers on a case-by-case basis, but no positive coverage decisions have been made.

Prior to the commercialization of AlloSure, we generated a strong body of clinical evidence. In late 2015, we announced the completion of analytical validation of AlloSure. Samples used in the analytical validation included donor recipient pairs with unrelated as well as closely related family members. A report describing the analytical validation of AlloSure including clinical validation information for heart transplant appeared in the November 2016 issue of The Journal of Molecular Diagnostics.

In May 2015, we initiated the Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Acute Rejection in Kidney Transplant Recipients, or DART, trial. The first publication of results from the DART trial in March 2017 described the validation of the clinical performance characteristics of dd-cfDNA in detecting rejection in kidney allograft recipients. DART is a multicenter observational study of kidney transplant recipients where blood specimens are drawn periodically after transplant during follow up visits and also after treatment for acute rejection. Patients were followed in DART for up to 24 months. We completed the first analysis of the data from DART in June 2016. By the time of completion of the first analysis, 400 patients had enrolled in DART in 14 centers and we had collected specimens from over 1,260 patient visits. As of March 31, 2018, we had over 2,100 patient visits. The data analyses demonstrated that increased levels of dd-cfDNA, determined by the AlloSure assay, discriminated active rejection more effectively than serum creatinine values. In collaboration with clinical investigators, we published these findings in the scientific peer-reviewed Journal of the American Society of Nephrology and the Journal Applied Laboratory Medicine in March 2017.

In late 2017, we established the Kidney Allograft Outcomes AlloSure Registry, or K-OAR, study to develop further data on the clinical utility of AlloSure for surveillance of kidney transplant recipients. We will invite 35 centers to join K-OAR, and we anticipate staggered activation of these study centers throughout 2018. As of March 31, 2018, 12 centers have been initiated as K-OAR study sites.

During the first three months of 2018, there were 1,051 AlloSure patient test results provided. Since launch, AlloSure has been ordered by 52 kidney transplant centers in the United States.

### Pre-Transplant Products

The Company develops, manufactures, markets and sells products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP® is used to type Human Leukocyte Antigen, or HLA alleles, based on the sequence specific primer, or SSP technology. Olerup SBTTM is a complete product range for sequence-based typing of HLA alleles. Olerup QTYPE® enables speed and precision in HLA typing at a low to intermediate resolution for samples that require a fast turn-around-time and uses real-time polymerase chain reaction, or PCR methodology. QTYPE received CE mark certification on April 10, 2018.

### Recent Highlights

- Accelerated AlloSure penetration in key kidney transplant centers
- As of March 31, 2018, 52 transplant centers have provided AlloSure testing to patients
- Continued progress in AlloSure K-OAR enrollment, with 12 centers initiated as of March 31, 2018
- Achieved total revenue of $14.1 million for the first quarter of 2018, up 21% year-over-year
- Testing revenue of $10.6 million, with 1,051 AlloSure and 3,847 AlloMap patient results provided
- Product revenue of $3.3 million
- Broadened testing and product offerings
- Entered into partnership with Illumina to develop and sell its Next Generation Sequencing transplant solutions
- Launched HeartCare, a comprehensive solution for surveillance of heart transplant patients, combining AlloMap with AlloSure-Heart
- Validated Olerup QTYPE on multiple platforms and received CE mark certification
- Refinanced outstanding debt
- On April 17, 2018, the Company entered into a new credit agreement with Perceptive for an initial term loan of $15.0 million and repaid the outstanding indebtedness to Danske Bank and the Allenex Former Majority Shareholders.

### Financial Operations Overview

#### Revenue

We derive our revenue from testing services, products sales and license and other revenues. On January 1, 2018, we adopted the new revenue accounting standard *Revenue from Contracts with Customers (Topic 606)* ("ASC 606") using the modified retrospective method. The adoption of ASC 606 resulted in a one-time adjustment of $2.9 million to accounts receivable and retained earnings. This adjustment reflects the estimated payment to be received for tests where the result had been delivered at December 31, 2017, but the associated revenue had not been recognized by December 31, 2017, because payment had not been received. Under the new accounting standard, revenue is recorded considering a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.

#### Testing Revenue

Our testing revenue is derived from AlloMap and AlloSure tests, which represented 75% of our total revenues for the three months ended March 31, 2018, and 68% of our total revenues for the three months ended March 31, 2017, respectively. We currently market AlloMap and AlloSure to healthcare providers through our direct sales force that targets transplant centers and their physicians, coordinators and nurse practitioners. The healthcare providers that order the tests and on whose behalf we provide our testing services are generally not responsible for the payment of these services. Amounts received by us vary from payer to payer based on each payer’s internal coverage practices and policies. We generally bill third-party payers upon delivery of an AlloMap or AlloSure test result report to the healthcare provider. As such, we take the assignment of benefits and the risk of collection from the third-party payer and individual patients.

#### Product Revenue

Our product revenue is derived primarily from sales of Olerup branded products. Product revenue represented 24% and 32% of total revenue for the three months ended March 31, 2018 and 2017, respectively. Product revenue is recognized from the sale of products to end-users, distributors and strategic partners when all revenue recognition criteria are satisfied, which is generally upon the product shipment.

#### License and Other Revenue

License agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. Our performance obligations under the license agreements may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees. We make judgments that affect the periods over which we recognize revenue. We review our estimated periods of performance based on the progress under each arrangement and account for the impact of any change in estimated revenues.

We did not recognize any revenue connected with milestones during the three months ended March 31, 2018 or 2017.

#### Cost of Testing

Cost of testing reflects the aggregate costs incurred in delivering the Company’s testing services. The components of cost of testing are materials and service costs, direct labor costs, stock-based compensation, equipment and infrastructure expenses associated with testing samples, shipping, logistics and specimen processing charges to collect and transport samples and allocated overhead including rent, information technology, equipment depreciation, utilities and royalties. Prior to adoption of the new revenue guidance, we recorded cost of testing associated with performing tests (except royalties) in the period when tests were performed without consideration if revenue was recognized in the same period. With the adoption of the new revenue standard on January 1, 2018, revenue and cost of testing for tests performed are recognized in the same period. Royalties for licensed technology, calculated as a percentage of test revenues, are recorded as license fees in cost of testing at the time the test revenues are recognized.

#### Cost of Product

Cost of product reflects the aggregate costs incurred in delivering our products to customers. The components of cost of product are material costs, manufacturing and kit assembly costs, direct labor costs, including equipment and infrastructure expenses associated with preparing kitted products for shipment, shipping, distributorship agreements and allocated overhead, including rent, information technology, equipment depreciation and utilities. Cost of product also includes amortization of acquired developed technology and adjustments to inventory values, including write-down of impaired, slow moving or obsolete inventory.

#### Research and Development Expenses

Research and development expenses, including clinical operations, represent costs incurred to develop new pre- and post-transplant diagnostic solutions, high quality evidence to support use of our tests, as well as continued efforts related to improving our existing product lines. These expenses include payroll and related expenses, consulting expenses, laboratory supplies, clinical studies and certain allocated expenses as well as amounts incurred under certain collaborative agreements. Research and development costs are expensed as incurred. We record accruals for estimated study costs comprised of work performed by contract research organizations under contract terms.

#### Sales and Marketing Expenses

Sales and marketing expenses represent costs incurred to sell, promote and increase awareness of our existing products and services to transplant centers and hospital laboratories. These efforts also include education of patients, clinicians, payers, and other relevant decision makers. Sales and marketing expenses include payroll and related expenses, educational and promotional expenses, and infrastructure expenses, including allocated facility and overhead costs. Compensation related to sales and marketing includes annual salaries and eligibility for periodic commissions or bonuses based on the achievement of predetermined sales goals or other management objectives.

#### General and Administrative Expenses

General and administrative expenses include costs for our executive, finance, accounting and human resources functions. Costs consist primarily of payroll and related expenses, professional service fees related to audit and accounting, certain financing transaction expenses, and legal and other contract and administrative services. We will continue to incur expenses as a result of operating as a public company.

#### Goodwill Impairment

We test goodwill and indefinite-lived intangibles for impairment at least annually and more frequently if impairment indicators are present. In the three months ended March 31, 2017, we determined that the decrease in our market capitalization constituted an indicator of impairment and therefore a goodwill impairment test was completed as of March 31, 2017. We identified an impairment of $2.0 million related to the goodwill allocated to the Pre-Transplant reporting unit.

No goodwill impairment indicators were present in the three months ended March 31, 2018 and therefore no impairment was recorded.

#### Change in Estimated Fair Value of Contingent Consideration

We revalue our contingent consideration obligation liability in connection with our acquisition of ImmuMetrix in 2014 at each reporting period. Changes in the fair value of our contingent consideration obligation are recognized as a component of operating expense within our condensed consolidated statements of operations.

#### Interest Expense

Interest expense is associated with borrowings under our loan agreements and also includes debt discount amortization.

#### Other Expense

Other expense includes gains and losses on foreign currency transactions, on debt extinguishment, and other miscellaneous expenses. During the three months ended March 31, 2018 we recorded $2.8 million loss on the conversion of the JGB debt as the difference between the value of the shares of common stock issued on the days of conversion and the amount of principal debt converted on those days, net of the allocated debt discount and derivative liability balances.

#### Change in Estimated Fair Value of Common Stock Warrant Liability and Derivative Liability

Common stock warrants issued in connection with our debt and equity financings are considered freestanding financial instruments and are analyzed as to whether they meet equity or liability classification in accordance with US GAAP. Warrants that meet liability classification are re-measured at each period end with changes in fair value recorded in our condensed consolidated statements of operations until these warrants are exercised or expire. On January 1, 2018, we adopted new accounting standard ASU 2017-11, *Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral of Mandatorily Redeemable Financial Instruments of Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception* and this resulted in the liability balance for our warrants issued to JGB being reclassified to equity on the date of adoption.

The JGB debt included certain embedded derivatives that required bifurcation, including settlement and penalty provisions. The embedded derivative was remeasured at each reporting period with changes recorded in change in estimated fair value of common stock warrant liability and derivative liability in the condensed consolidated statements of operations. As of March 27, 2018, the JGB debt had fully converted to shares of our common stock. The change in the fair market value of the derivative liability through to March 27, 2018 was recorded in change in estimated fair value of common stock warrant liability and derivative liability in the condensed consolidated statements of operations.

### Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Our significant accounting policies are described in Note 2 of the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information. Some of these accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. We believe that the following critical accounting policies reflect the more significant estimates and assumptions used in the preparation of our financial statements. We believe the following critical accounting policies are affected by significant judgments and estimates used in the preparation of our Condensed Consolidated Financial Statements:

- Revenue recognition – estimation of variable consideration
- Determination of the accruals for clinical studies,
- Inventory valuation
- Valuation of common stock warrant liability
- Valuation of embedded derivative liability
- Valuation and impairment of goodwill, intangible assets and other long-lived assets;
- Goodwill and acquired intangible assets
- Share-based compensation; and
- Accounting for income taxes.

There were no material changes in the matters for which we make critical accounting estimates in the preparation of our Condensed Consolidated Financial Statements during the three months ended March 31, 2018 as compared to those disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our annual report on Form 10-K for the year ended December 31, 2017, except as discussed in Note 2, Summary of Significant Accounting Policies, to the Condensed Consolidated Financial Statements in this quarterly report.

### Recently Issued Accounting Standards

Refer to Note 2, Summary of Significant Accounting Policies - recent accounting Pronouncements, of the Notes to Condensed Consolidated Financial Statements in this quarterly report for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial position and cash flows.

### Results of Operations

### Comparison of the Three Months Ended March 31, 2018 and 2017

### (In thousands)

| Revenue: | Three Months Ended March 31, 2018 | 2017 | Change |
| --- | ---: | ---: | ---: |
| Testing revenue | $10,604 | $7,902 | $2,702 |
| Product revenue | 3,307 | 3,667 | (360) |
| License and other revenue | 142 | 15 | 127 |
| Total revenue | 14,053 | 11,584 | 2,469 |
| Operating expenses: |  |  |  |
| Cost of testing | 4,112 | 3,057 | 1,055 |
| Cost of product | 2,272 | 2,327 | (55) |
| Research and development | 3,368 | 3,283 | 85 |
| Sales and marketing | 4,085 | 3,222 | 863 |
| General and administrative | 5,307 | 6,502 | (1,195) |
| Goodwill impairment | — | 1,958 | (1,958) |
| Change in estimated fair value of contingent consideration | 144 | (221) | 365 |
| Total operating expenses | 19,288 | 20,128 | (840) |
| Loss from operations | (5,235) | (8,544) | 3,309 |
| Interest expense | (2,695) | (790) | (1,905) |
| Other expense, net | (2,809) | (686) | (2,123) |
| Change in estimated fair value of common stock warrant liability and derivative liability | 1,321 | 4,128 | (2,807) |
| Income tax benefit | 424 | 283 | 141 |
| Net loss | (8,994) | (5,609) | (3,385) |
| Net loss attributable to noncontrolling interest | (25) | (47) | 22 |
| Net loss attributable to CareDx, Inc. | $(8,969) | $(5,562) | $(3,407) |

#### Testing Revenue

Testing revenue increased by $2.7 million, or 34%, for the three months ended March 31, 2018 as compared to the same period in 2017. The increase is mainly due to the 1,051 AlloSure test results provided in the three months ended March 31, 2018, following the launch of AlloSure in October 2017, the increase in AlloMap test results provided from the 3,847 in the first three months ended March 31, 2018, compared to 3,750 in the same period in 2017, and the January 1, 2018, change in the Medicare reimbursement rate for AlloMap from $2,840 to $3,240.

As described in Note 2 of the Condensed Consolidated Financial Statements, the adoption of ASC 606 on January 1, 2018, had an immaterial impact on Testing Revenue for the three months ended March 31, 2018, as compared to the three months ended March 31, 2017.

#### Product Revenue

Product revenue decreased by $0.4 million, or 10%, for the three months ended March 31, 2018, compared to the same period in 2017.

#### License and Other Revenue

License, and other revenue increased by $0.1 million for the three months ended March 31, 2018, reflecting royalty revenue under our services agreement with CardioDx for which none was received in the same period in 2017.

#### Cost of Testing

Cost of testing increased by approximately $1.0 million, or 35%, for the three months ended March 31, 2018, compared to the same period in 2017, primarily due to the increase in test results provided for both AlloMap and AlloSure.

#### Cost of Product

Cost of product decreased by less than $0.1 million, or 2%, for the three months ended March 31, 2018, compared to the same period in 2017. The decrease in cost of product in the three months ended March 31, 2018 mainly reflects a decrease in sales for the period, partially offset by an increase in scrap and inventory obsolescence.

#### Research and Development

Research and development expenses increased by less than $0.1 million, or 3%, for the three months ended March 31, 2018, compared to the same period in 2017 due to an increase in registry study costs of $0.1 million.

#### Sales and Marketing

Sales and marketing expenses increased by approximately $0.9 million, or 27%, for the three months ended March 31, 2018, compared to the same period in 2017, primarily due to higher personnel costs of $0.5 million, increased travel expenses of $0.2 million, and a $0.2 million increase in marketing expenses.

#### General and Administrative

General and administrative expenses decreased by $1.2 million, or 18%, for the three months ended March 31, 2018, compared to the same period in 2017. This decrease primarily reflects a $1.3 million reduction in audit and tax fees in 2018 as compared to the 2017 period.

#### Goodwill Impairment

In the three months ended March 31, 2017, we determined that the decrease in our market capitalization constituted an indicator of impairment and therefore a goodwill impairment test was completed as of March 31, 2017. We recorded a goodwill impairment charge of $2.0 million as of March 31, 2017. No impairment was identified in the three months ended March 31, 2018.

#### Change in Estimated Fair Value of Contingent Consideration

We estimate the contingent consideration liability fair value at each period end based on our common stock price at the end of the period and a probability of meeting the contractual milestone related to the number of tests sold by June 2020, in accordance with the ImmuMetrix acquisition agreement. We recognized a non-cash loss of $0.1 million and a non-cash gain of $0.2 million for the three months ended March 31, 2018 and 2017 respectively.

#### Interest Expense

Interest expense increased by $1.9 million for the three months ended March 31, 2018, compared to the same period in 2017. This increase primarily consists of $1.8 million JGB Debt discount amortization, which was not included in the same period ended March 31, 2017 as the JGB debt was entered into on March 15, 2017.

#### Other Expense, Net

Other expense increased $2.1 million in the three months ended March 31, 2018 compared to 2017. A loss of $2.8 million for the conversion of the JGB debt in the three months ended March 31, 2018, was offset by $0.3 million debt advisory fees, $0.2 million debt extinguishment costs, and additional foreign currency losses in the three months ended March 31, 2017. The $2.8 million loss on the conversion of the JGB debt resulted from the difference between the value of the shares of common stock issued on the days of conversion and the amount of principal debt converted on those days, net of debt discount and embedded derivative liability.

#### Change in Estimated Fair Value of Common Stock Warrant Liability and Derivative Liability

The change in estimated fair value of common stock warrant liability and derivative liability was $1.3 million income in the three months ended March 31, 2018 and $4.1 million income in the comparative period in 2017.

The $1.3 million income in the three months ended March 31, 2018, comprised of $2.5 million of income related to the changes in fair value of the JGB debt embedded derivative liability and $1.2 million of expense related to the change in value of our common stock warrant liability.

The $4.1 million income in the three months ended March 31, 2017, comprised a remeasurement gain of $3.3 million related to the changes in fair value of common stock warrant liability and $0.8 million of income related to the changes in fair value of JGB debt embedded derivative between March 15, 2017, the issuance date, and March 31, 2017. The remeasurement gains in the three months ended March 31, 2017 reflect the decline in the price of shares of our common stock during this period.

As of January 1, 2018, we adopted the new accounting standard and reclassified the outstanding common stock warrant issued in connection with the JGB debt to equity. This warrant is not re-measured through earnings after January 1, 2018. Warrants issued in connection with Private Placement and Subsequent Financing during 2016 continue to be classified as liability and will be re-measured at the end of each reporting period until expired or exercised. Changes in the common stock fair value, estimated volatility and expected contractual term will significantly impact the fair value of the warrant liability.

#### Income Tax Benefit

For the three months ended March 31, 2018, we recorded an income tax benefit of $0.4 million on a loss before income taxes of $9.4 million. This benefit primarily resulted from the expectation that amortization of the various intangible assets acquired, when completed and placed in service, is not expected to be deductible for tax purposes. Accordingly, a deferred tax liability was recorded at the acquisition date for the difference between the financial reporting and tax basis of the intangibles.

### Cash Flows for the Three Months Ended March 31, 2018 and 2017

The following table summarizes the primary sources and uses of cash for the periods presented:

*(in thousands)*

| Net cash (used in) provided by: | Three Months Ended March 31, 2018 | 2017 |
| --- | ---: | ---: |
| Operating activities | $(4,518) | $(6,741) |
| Investing activities | (754) | (68) |
| Financing activities | (2,318) | 11,131 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 17 | 17 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $(7,573) | $4,339 |

#### Operating Activities

Net cash used in operating activities consists of net loss, adjusted for certain noncash items in the statement of operations and changes in operating assets and liabilities. Cash used in operating activities for the three months ended March 31, 2018 was $4.5 million. Our net loss of $9.0 million was our primary use of cash in operating activities and included a number of noncash items. Our noncash items included $2.8 million loss on the conversion of debt to shares of our common stock, $2.0 million of amortized debt discount related to the conversion of the JGB debt, and $1.3 million net gain on the revaluation of warrant and derivative liability to estimated fair value. Net operating assets decreased by $1.1 million.

Cash used in operating activities for the three months ended March 31, 2017 was $6.7 million. Our net loss of $5.6 million was our primary use of cash in operating activities; which also included a number of noncash items. Our noncash items included uses of cash due to a $4.1 million gain on revaluation of warrants and derivative liabilities to estimated fair value and $0.2 million gain on a contingent consideration liability related to our acquisition of IMX in June 2014, partially offset by $2.0 million of goodwill impairment related to our purchase of Allenex, $0.9 million of depreciation and amortization, $0.6 million of amortization of debt discount and noncash interest expense, $0.4 million of stock-based compensation. Net operating assets decreased $0.7 million.

#### Investing Activities

For the three months ended March 31, 2018, net cash used in investing activities was less than $0.7 million related to the acquisition of the Allenex AB minority interest and purchases and disposals of property and equipment.

For the three months ended March 31, 2017, net cash used in investing activities was $0.1 million, primarily related to purchases of property and equipment.

#### Financing Activities

Net cash used in financing activities for the three months ended March 31, 2018 of $2.3 million was primarily related to the repayment of the SSP Primers Note of $1.2 million, debt issuance fees of $0.6 million in connection with the term loan agreement with Perceptive Credit Holdings II, LP, or Perceptive, and the quarterly Danske bank term loan facility amortization of $0.4 million as well as a reduction in the outstanding balance of the Danske credit facility of $0.2 million.

Net cash provided by financing activities for the three months ended March 31, 2017 of $11.1 million consisted primarily of $24.0 million in net proceeds received from the JGB debt agreement in March 2017, partly offset by $12.9 million of principal payments on debt and capital lease obligations.

### Liquidity and Capital Resources

We have incurred significant losses and negative cash flows from operations since our inception and had an accumulated deficit of $274.1 million at March 31, 2018. As of March 31, 2018, we had cash and cash equivalents of $18.7 million, and $10.2 million of debt outstanding under our debt obligations, of which $0.5 million was current.

On April 17, 2018, we entered into a new credit agreement with Perceptive for an initial term loan of $15.0 million and repaid the outstanding indebtedness of the Allenex Notes and the Danske bank term loan facility and credit facility. A second tranche of $10.0 million will be available at our option subject to the satisfaction of customary conditions.

#### Deferred Purchase Consideration

On November 14, 2017 we entered into amendments to the Conditional Share Purchase Agreement with the Former Majority Shareholders, whereby we immediately repaid the total remaining deferred purchase consideration of $4.7 million, plus accrued interest.

#### Allenex Notes and Danske Bank Term Loan

All outstanding amounts under the Allenex Notes of $4.4 million and Danske bank term loan facility and credit facility of $6.7 million were repaid on April 17, 2018 with proceeds from the Perceptive term loan refinancing.

We were not in compliance with certain quarterly covenants on December 31, 2017 or March 31, 2018, as related to Danske bank term loan. We classified $0.5 million as current debt and $9.7 as long-term debt in accordance with accounting standards as related to refinancing short-term obligations with long-term debt as of March 31, 2018.

#### JGB Debt

On March 1, 2018, we notified JGB of our intent to prepay on April 13, 2018, in full the outstanding principal and interest under the JGB Debentures. During the three months ended, March 31, 2018, JGB converted all outstanding $26.7 million of principal and accrued interest of the JGB debt into an aggregate of 6,161,331 shares of our common stock. Restricted cash of $9.4 million was released from any restrictions after the conversion and included in our cash and cash equivalent balance as of March 31, 2018.

#### Going Concern

As of March 31, 2018, we had cash and cash equivalents of $18.7 million and an accumulated deficit of $274.1 million. On April 17, 2018, we entered into a new credit agreement with Perceptive for an initial term loan of $15.0 million and repaid the outstanding indebtedness of the Allenex Notes and the Danske bank term loan facility and credit facility. A second tranche of $10.0 million will be available at our option subject to the satisfaction of customary conditions.

We may require additional financing in the future to fund working capital and pay our obligations as they come due. Additional financing might include one or more offerings and one or more of a combination of equity securities, debt arrangements or collaborations. However, there can be no assurance that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable to us. We believe that the net proceeds from the Perceptive refinancing, as well as our existing cash balance and expected revenues, will be sufficient to meet our anticipated cash requirements for at least the next 12 months.

### Factors Affecting Our Performance

#### The Number of AlloMap and AlloSure Tests We Receive and Report

The growth of our post-transplant business is tied to the number of AlloMap and AlloSure tests we receive and report. Historically, less than two percent of AlloMap tests received are not reported due to improper sampling, damage in transit or other causes. We incur costs in connection with collecting and shipping all samples and a portion of the costs when we cannot ultimately issue a test report. As a result, the number of samples received largely correlates directly to the number of test reports.

#### The Number of Pre-Transplant Diagnostic Products We Sell

The growth of our pre-transplant business is tied to the sales of the Olerup SSP, Olerup QTYPE, and Olerup SBT product lines. The pre-transplant sales organization is located in Stockholm, Sweden; Vienna, Austria; Fremantle, Australia and West Chester, Pennsylvania. Pre-transplant products are sold directly to customers in 12 countries. The pre-transplant business also uses distributors to sell in approximately 60 countries.

#### Continued Adoption of and Reimbursement for AlloMap

AlloMap test volume and the corresponding reimbursement revenue has generally increased over time since the launch of AlloMap, as Medicare provided reimbursement and payers adopt coverage policies and fewer payers consider AlloMap to be experimental and investigational. The rate at which our tests are covered and reimbursed has, and is expected to continue to vary by payer. Revenue growth depends on our ability to maintain Medicare reimbursement, achieve broader reimbursement from third party payers and to expand the number of tests per patient and the base of healthcare providers.

On June 10, 2016, Centers for Medicare & Medicaid Services, or CMS, announced proposed changes in reimbursement for a number of established molecular diagnostic tests, including AlloMap. Under the gapfill reimbursement rate for 2017, AlloMap reimbursement for patients covered by Medicare would have been reduced from $2,821 to $1,921, effective January 1, 2017. This reimbursement rate, determined by gapfill submissions from the Medicare contractors, was open to reconsideration until October 31, 2016. We submitted a request for reconsideration of the reimbursement rate determined by the Medicare contractors and in November 2016 CMS released the final 2017 Clinical Laboratory Fee Schedule reflecting the rate of reimbursement at $2,841 for AlloMap.

The Protecting Access to Medicare Act of 2014, or PAMA, includes a substantial new payment system for clinical laboratory tests under the CLFS. Under PAMA, laboratories that receive the majority of their Medicare revenues from payments made under the CLFS would report initially and then on a subsequent three-year basis thereafter (or annually for advanced diagnostic laboratory tests, or ADLTs), private payer payment rates and volumes for their tests. The final PAMA ruling was issued June 17, 2016 indicating that data for reporting for the new PAMA process would begin in 2017 and the new market based rates took effect on January 1, 2018. Effective January 1, 2018, Medicare plans to reimburse us $3,240 for AlloMap testing of Medicare beneficiaries, which represents a 14% increase over the 2017 reimbursement rate. AlloMap has also received positive coverage decisions for reimbursement from many of the largest U.S. private payers, including Aetna, Anthem, Cigna, Health Care Services Corporation (HCSC), Humana, Kaiser Foundation Health Plan, Inc., and TRICARE.

#### Reimbursement for AlloSure

On September 26, 2017 we received notice that the Molecular Diagnostics Services, or MolDX, Program developed by Palmetto GBA has set AlloSure reimbursement at $2,841. Effective October 9, 2017, AlloSure was made available for commercial testing with Medicare coverage and reimbursement. We believe the use of AlloSure, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a kidney transplant. In particular, we believe AlloSure can improve patient care by helping healthcare providers to reduce the use of invasive biopsies and determine the appropriate dosage levels of immunosuppressants.

#### Development of Additional Products

We rely on sales of AlloMap, AlloSure, Olerup SSP, Olerup SBT and Olerup QTYPE to generate the majority of our revenue. Our product development pipeline includes other transplant diagnostic solutions to help clinicians and transplant centers make personalized treatment decisions throughout a transplant patient’s lifetime. We expect to invest in research and development in order to develop additional products. Our success in developing new products will be important in our efforts to grow our business by expanding the potential market for our products and diversifying our sources of revenue.

#### Timing of Research and Development Expenses

Our spending on experiments may vary substantially from quarter to quarter. We also expend funds to secure clinical samples that can be used in discovery, product development, clinical validation, utility and outcome studies. The timing of these research and development activities is difficult to predict. If a substantial number of clinical samples are acquired in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses will affect our financial results. We conduct clinical studies to validate our new products, as well as on-going clinical and outcome studies to further the published evidence to support our commercialized AlloMap and AlloSure tests. Spending on research and development for both experiments and studies may vary significantly by quarter depending on the timing of these various expenses.

### Contractual Obligations

We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information required under this item.

### Off-Balance Sheet Arrangements

As of March 31, 2018, we had no off-balance sheet arrangements as defined under Regulation S-K 303(a)(4) of the Exchange Act, and the instructions thereto.

### JOBS Act Accounting Election

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

### Foreign Operations

The accompanying condensed consolidated balance sheets contain certain recorded assets in foreign countries, namely Stockholm, Sweden, Vienna, Austria and Fremantle, Australia. Although these countries are considered economically stable and we have experienced no notable burden from foreign exchange transactions, export duties or government regulations, unanticipated events in foreign countries could have a material adverse effect on our operations.

## Market risk

As filed, 2,153 characters.

#### Interest Rate Risk

We are exposed to market risks in the ordinary course of our business. We had cash and cash equivalents of $18.7 million and $16.9 million at March 31, 2018 and December 31, 2017, respectively, which consisted of bank deposits and money market funds. Additionally, we had debt of $10.2 million and $34.1 million as of March 31, 2018 and December 31, 2017, respectively. Such variable interest-bearing instruments carry a degree of risk. However, we have not been exposed to, nor do we anticipate being exposed to, material risks due to changes in interest rates. A hypothetical fifty basis point increase or decrease in interest rates would have an immaterial impact on our unaudited condensed consolidated financial statements.

#### Foreign Currency Exchange Risk

Our pre-transplant business has operations in Sweden, Austria, Australia and sells to other countries throughout the world. As a result, we are subject to significant foreign currency risks, including transacting in foreign currencies, investment in a foreign entity, as well as assets and debts denominated in foreign currencies. Our testing revenue is primarily denominated in U.S. dollars. Our product revenue is denominated primarily in Swedish Krona, the Euro, the Australian dollar and U.S. dollars. Consequently, our revenue denominated in foreign currency is subject to foreign currency exchange risk. A portion of our operating expenses are incurred outside of the U.S. and are denominated in Swedish Krona, the Euro, and the Australian Dollar, which are also subject to fluctuations due to changes in foreign currency exchange rates. An unfavorable 10% change in foreign currency exchange rates for our assets and liabilities denominated in foreign currencies at March 31, 2018, would have negatively impacted our financial results for the three months ended March 31, 2018 by $0.2 million. Currently, we do not have any near-term plans to enter into a formal hedging program to mitigate the effects of foreign currency volatility. We will continue to reassess our approach to managing our risk relating to fluctuations in foreign currency exchange rates.

## Controls and procedures

As filed, 1,957 characters.

### Evaluation of Disclosure Controls and Procedures

Management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(b) and 15d-15(e) promulgated under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that we are required to apply our judgment in evaluating the benefits of possible controls and procedures relative to our costs. Based on such evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective at the reasonable assurance level and are effective to provide reasonable assurance that information required to be disclosed in the reports we file and submit under the Exchange Act, is (i) recorded, processed, summarized and reported as and when required and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely discussion regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended March 31, 2018 that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 3,353 characters.

Our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 22, 2018, Part I –Item 1A, Risk Factors, describes important risk factors that could cause our business, financial condition, results of operations and growth prospects to differ materially from those indicated or suggested by forward-looking statements made in this Quarterly Report on Form 10-Q or presented elsewhere by management from time to time. There have been no material changes in the risk factors that appear in Part I - Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 22, 2018 other than those listed below. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business.

***Our debt agreement contains restrictive and financial covenants that may limit our operating flexibility.***

Our debt agreement with Perceptive Credit Holdings II, LP, or Perceptive, contains certain restrictive covenants that limit our ability to merge with other companies or consummate certain changes of control, acquire other companies, make certain investments or acquisitions, pay dividends, transfer or dispose of assets, amend certain material agreements, incur additional indebtedness, permit additional liens or enter into various specified transactions. We therefore may not be able to engage in any of the foregoing transactions unless we obtain the consent of the lender or terminate our existing debt agreement. There is no guarantee that we will be able to generate sufficient cash flow or sales to pay the principal and interest under our debt agreement.

Refer to Note 17 of the notes to the unaudited condensed consolidated financial statements included in Part I, Item I of this Quarterly Report on Form 10-Q for details on debt agreement with Perceptive.

***Our License and Commercialization Agreement with Illumina may not result in material benefits to our business.***

Pursuant to our License and Commercialization Agreement with Illumina, or the Illumina License Agreement, we acquired the worldwide distribution, development and commercialization rights to Illumina, Inc.’s next generation sequencing product line for use in the field of bone marrow transplantation diagnostic testing and solid organ transplantation diagnostic testing.

Under the Illumina License Agreement, we are obligated to complete timely development and commercialization of future products, including meeting certain commercialization milestones. The failure to meet any such milestones could result in the loss of exclusivity for the affected licensed products. Additionally, we agreed to minimum purchase commitments of finished products and raw materials from Illumina, Inc. through 2023 and we are required to pay royalties in the mid-single to low-double digits on sales of future commercialized products.

We cannot make any assurances that our efforts under the Illumina License Agreement will be successful. As a result, we may not be able to fully realize the anticipated strategic benefits of the Illumina License Agreement. If we fail to successfully execute on the Illumina License Agreement, we may not realize the benefits expected from the transaction and our business may be harmed.

Filed May 10, 2018.
Source: SEC EDGAR, the filing index for accession 0001564590-18-013045. Last ingested by Listed: Nov 13, 2026, 16:18 ET. No prices; not investment advice.
